Cannabix's Breath
Logix Alcohol Device Delivers Positive Impact to Private Monitoring
Agency in Montana, USA
Cannabix
is developing alcohol and marijuana breathalyzer devices to give
law enforcement, employers and other organizations tools to enhance
public safety
Vancouver, British Columbia, Canada
-- April 25, 2024 -- InvestorsHub NewsWire -- Cannabix Technologies
Inc. (CSE:
BLO) (OTC
PINK: BLOZF) (Frankfurt: 8CT) (the "Company or Cannabix")
developer of alcohol and marijuana breathalyzer screening devices
for law enforcement and the workplace reports that Friedel, LLC
("Friedel Clinic") a private monitoring agency, based in Montana
has deployed the Breath Logix Alcohol Breathalyzer (formerly known
as the "CAB" product offering) under its 24/7 Sobriety
Program.
Under the 24/7 Sobriety
Program, participants, as a condition to their probation release,
are scheduled for twice daily alcohol breath testing at designated
locations within the state. The Company reports that the Breath
Logix device has been used daily, collecting over a thousand breath
samples autonomously. The device captures user photos to confirm
and record identity, and delivers near instantaneous Blood Alcohol
Content (BAC) breath results.
Probation Officer, Neil Friedel
stated, "In a relatively short period of time the Breath Logix
device has become an invaluable device under our 24/7 Sobriety
Program. The device allows our clients to autonomously get tested
for breath alcohol without the need for our clinic to station a
full-time administrator -- its a game changer for us. Our clinic is
saving time and money daily with the Breath Logix device deployed
in our office. It has quickly become part of our daily routine and
work flow process in our clinic."
The Friedel Clinic has a robust drug
testing operation and is one of the top drug and alcohol testing
providers to the judicial system and employers within the state of
Montana. The high-volume clinic has a diverse range of patients and
focuses on private sector testing for alcohol and illicit
drugs.
Figure
1. Breath Logix
Industrial
Series Wall Mounted Alcohol
Breathalyzer. Contactless and straw test modes
available.
24/7 Sobriety Program in the
United States
Cannabix has been piloting its Breath
Logix Alcohol screening device as a new solution for the 24/7
Sobriety Program, which exists in several states in the United
States. This program seeks to reduce the re-arrests of individuals
previously convicted of driving while under the influence (DUI) of
alcohol or drugs through daily breath testing.
In a 24/7 Sobriety Program, offenders
are scheduled for twice daily alcohol testing at select locations
in a given state or county. Currently the program requires
dedicated employees to administer alcohol tests with a handheld
alcohol breathalyzer throughout the day. The Breath Logix could
revolutionize the program by delivering autonomous collection and
reporting of alcohol results to administrators leading to
significant savings and process efficiency.
Breath Logix
Industrial
Series Features
The Breath Logix Industrial
Series is a weather
resistant device with a host of requested features including patent
pending pre-calibrated cartridge technology which will allow site
safety administrators to easily maintain their devices, and
eliminate the need for costly calibration equipment and
time-consuming site visits from technicians for maintenance.
This device can be used for
pre-access alcohol testing, random testing, start-of-shift testing,
pre-employment testing, return-to-work testing, post-incident
testing and for the 24/7 Sobriety Program.
The Breath Logix Alcohol device
automatically checks the sobriety of a user and can take a picture
to confirm and record identity while a breath sample is being
delivered. Upon detection of positive breath alcohol result, the
device will deliver a precise BAC level on the screen, and send a
real-time alert via text message, e-mail and to a dedicated web
portal. Furthermore, the system logs user BAC for incident
reporting and historical investigations. The Breath Logix helps organizations
save money by deploying an autonomous alcohol screening device
which eliminates the need for dedicated alcohol screening
administrators using conventional handheld devices.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana and alcohol breathalyzer technologies for
law enforcement, workplaces and laboratories. Cannabix is
developing delta-9 THC and alcohol screening devices. Delta-9 THC
is the psychoactive component of marijuana that causes impairment.
Breath testing for delta-9 THC would allow employers and law
enforcement to identify recent marijuana use.
Cannabix is the developer of Breath Logix Series of autonomous
breath alcohol detection devices for employers and a range of other
settings.
We seek Safe
Harbor.
On
behalf of the Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the
Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities. The Company is not currently selling
commercial breathalyzers. Actual results and future events could
differ materially from those anticipated in such information. These
and all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
501-3292 Production
Way, Burnaby, B.C., V5A 4R4
Phone: (604)
551-7831
Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
